Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) has provided an update.
Fusen Pharmaceutical Co., Ltd. has announced a board meeting scheduled for August 29, 2025, to review and approve the company’s unaudited interim results for the first half of the year and to consider declaring an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential shareholder returns.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and production of pharmaceutical products. The company is incorporated in the Cayman Islands and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 337,230
Technical Sentiment Signal: Sell
Current Market Cap: HK$261M
For detailed information about 1652 stock, go to TipRanks’ Stock Analysis page.